<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361812</url>
  </required_header>
  <id_info>
    <org_study_id>HS632-I</org_study_id>
    <nct_id>NCT04361812</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacokinetics and Safety of Recombinant Anti IgE Humanized Monoclonal Antibody for Injection(HS632) and Omalizumab With a Single Injection (Xolair®)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Controlled Phase I Clinical Trial Comparing the Pharmacokinetic and Safety Similarities of Recombinant Anti IgE Humanized Monoclonal Antibody for Injection (HS632) With Omalizumab (Xolair® ) After a Single Dose Administration in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the bioequivalence of HS632 and Omalizumab (Xolair®) in a single subcutaneous
      administration in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence of HS632 and Xolair® in single subcutaneous administration in healthy subjects</measure>
    <time_frame>24 months</time_frame>
    <description>Bioequivalence of HS632 and Xolair® in single subcutaneous administration in healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) (0 - t) of HS632 and Xolair® in single subcutaneous administration in healthy subjects</measure>
    <time_frame>24 months</time_frame>
    <description>The area under the plasma concentration versus time curve (AUC) from 0 to the last selected time point, i.e. 2184h after the injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</measure>
    <time_frame>24 months</time_frame>
    <description>Peak plasma concentration (Cmax) after single subcutaneous administration of HS632 and Xolair® in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) (0 -∞) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</measure>
    <time_frame>24 months</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) (0 -∞) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach peak plasma concentration (Tmax) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</measure>
    <time_frame>24 months</time_frame>
    <description>Time to reach peak plasma concentration (Tmax) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance corrected by bioavailability (CLt/F) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</measure>
    <time_frame>24 months</time_frame>
    <description>Total clearance corrected by bioavailability (CLt/F) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</measure>
    <time_frame>24 months</time_frame>
    <description>Half-life (T1/2) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution corrected by bioavailability (Vd/F) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</measure>
    <time_frame>24 months</time_frame>
    <description>Apparent volume of distribution corrected by bioavailability (Vd/F) of single subcutaneous administration of HS632 and Xolair® in healthy subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with treatment emergent adverse event (TEAE)</measure>
    <time_frame>24 months</time_frame>
    <description>percentage of participants with treatment emergent adverse event (TEAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of of the participants with anti-drug antibody( ADA) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</measure>
    <time_frame>24 months</time_frame>
    <description>percentage of of the participants with anti-drug antibody( ADA) of single subcutaneous administration of HS632 and Xolair® in healthy subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Similarity of Pharmacokinetics and Safety</condition>
  <arm_group>
    <arm_group_label>HS632</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omalizumab (Xolair®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection of Omalizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS632</intervention_name>
    <description>Subcutaneous injection of HS632</description>
    <arm_group_label>HS632</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab (Xolair®)</intervention_name>
    <description>Subcutaneous injection of Omalizumab Xolair®)</description>
    <arm_group_label>Omalizumab (Xolair®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Signing the informed consent and being able to complete the test according to the
             plan;

          -  2.Age ≥ 18 and ≤ 40 (subject to the date of signing the informed consent), male;

          -  3.The body mass index (BMI) is between 20and6 kg / m2 (including 20 kg / m2 and 26 kg
             / m2), and the body weight is between 50-75 kg (including 50 kg and 75 kg);

          -  4.During the trial period, the subjects or their spouses used appropriate and
             effective contraceptive measures, such as abstinence, oral contraceptives,
             intrauterine devices or double barrier method (such as condom plus contraceptive
             diaphragm).

        Exclusion Criteria:

          -  1.Patients with mental, respiratory, cardiovascular, digestive, urinary, reproductive,
             skeletal and motor, blood, endocrine, nervous and other system diseases, or patients
             with any previous immune diseases;

          -  2.Patients with severe bleeding factors affecting venous blood collection

          -  3.Skin diseases or other diseases affecting subcutaneous injection;

          -  4. Patients with upper respiratory tract infection or other acute infection in the 2
             weeks prior to screening;

          -  5.Patients with history of malignant tumor;

          -  6.Those who have undergone surgery within two months before signing the informed
             consent;

          -  7.Alcoholics or regular drinkers within 3 months before the test, i.e. those who drink
             more than 14 units of alcohol per week (14 bottles of 360 ml beer or 630 ml spirits
             with 40% alcohol or 2100 ml wine), or whose alcohol breath test is positive;

          -  8.Those who have used soft drugs (e.g., marijuana) within 3 months prior to signing
             the informed consent or hard drugs (e.g., cocaine, phencyclidine, etc.) within 1 year
             prior to the trial； those who have positive drug abuse test results (morphine,
             methamphetamine, ketamine, MDMA, tetrahydrocannabinolic acid, cocaine);

          -  9. Those who are addicted to smoking or smoke more than 5 cigarettes per day on
             average in the 3 months before signing the informed consent; or those who have
             positive nicotine results;

          -  10.Those who have a history of drug or food allergy, or who have special requirements
             for diet and cannot abide by the unified diet or specific allergy history (asthma,
             urticaria, eczema dermatitis, etc.); those who have allergic rhinitis, or are known to
             be allergic to any component of the test drug or latex (contained in the syringe
             needle cover);

          -  11.Those who drinking too much tea, coffee and / or caffeinated beverages (more than 8
             cups, 1 cup = 250 ml) every day;

          -  12. Those who have received any drug treatment (including prescription drugs,
             over-the-counter drugs, biological products, Traditional Chinese medicine, vitamins,
             dietary supplements, etc.) and health care products within 14 days before signing the
             informed consent;

          -  13. Traditional Chinese medicine (except proprietary Chinese Medicine) and health care
             products are planned to be used during the test;

          -  14. Have a blood donation history within 3 months before signing the informed consent,
             or plan to donate blood during the trial;

          -  15. Those who plan to accept any biological drugs within 3 months after the
             administration of the test drug or those who plan to accept monoclonal antibody drugs
             within 9 months;

          -  16. Those who plan to donate sperm within 6 months after the administration of the
             test drug;

          -  17. Those who plan to undergo (including cosmetic surgery, dental surgery and oral
             surgery) during the trial period;

          -  18. Those who plan to take part in strenuous exercise during the experiment, including
             physical contact exercise or collision exercise;

          -  19.Anti-drug antibody (ADA) test is positive;

          -  20. Participants in other clinical trials within 3 months before signing the informed
             consent;

          -  21. Vaccinated within 6 months before signing the informed consent;

          -  22. In the screening period or baseline period, the researchers think that the
             physical examination and laboratory examination of the subjects have clinical
             significance abnormalities; or the following indicators exceed the following
             standards: the rate of pulse in awake state is less than 50 times / min or more than
             100 times / min, the systolic pressure in sitting position is equal to or more than
             140 mmHg or the diastolic pressure is more than 90 mmHg, and the ear temperature is
             more than 37.5 ℃; any one of eosinophil, neutrophil, platelet is beyond the normal
             range; eGFR is less than 90 mL / min / 1.73m2 (estimated by MDRD formula of kidney
             disease diet improvement test, see Annex I);

          -  23. Patients with clinically significant ECG abnormalities in screening or baseline
             period, or with QTcF ≥ 450 ms, or with a history of clinically significant ECG
             abnormalities in the past;

          -  24. The results of chest X-ray examination or B-ultrasonic examination are clinically
             significant abnormalities according to the judgment of the researcher;

          -  25.Any one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponema pallidum
             antibody is positive;

          -  26. The researchers think those who are considered by the investigator unsuitable for
             the trail or who may not be able to complete the trial for other reasons is not
             suitable to be enrolled or may not be able to complete the experiment for other
             reasons;

          -  27. Employees or relatives of researchers, research centers, sponsors and contract
             research organizations.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhang Jing</last_name>
    <phone>13816357098</phone>
    <email>13816357098@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wu Xiaojie</last_name>
    <phone>13524686330</phone>
    <email>maomao_xj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhang Jing</last_name>
      <phone>13816357098</phone>
      <email>13816357098@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wu Xiaojie</last_name>
      <phone>13524686330</phone>
      <email>maomao_xj@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhu Leilei</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>He Qing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

